

2021 Medicare Part D Formulary Change

We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy restrictions on a drug (or move a drug to a higher cost-sharing tier), we will let you know of the change at least 30 days before the date that the change becomes effective. However, if the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and let you know.

The product changes noted below will be implemented on the Medicare Part D Plan:

New Added Products: **Effective 9/1/2021**

| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| bepotastine besilate 1.5 % eye drops | New Drug | Tier 2 | |
| INFANRIX (DTAP)(PF) 25 LF UNIT-58MCG-10 LF/0.5ML INTRAMUSCULAR SYRINGE | New Drug | Tier 2 | |
| JATENZO 158 MG CAPSULE | New Drug | Tier 4 | PA QL |
| JATENZO 198 MG CAPSULE | New Drug | Tier 4 | PA QL |
| JATENZO 237 MG CAPSULE | New Drug | Tier 4 | PA QL |
| LAZANDA 100 MCG/SPRAY NASAL SPRAY | New Drug | Tier 4 | PA QL |
| LAZANDA 400 MCG/SPRAY NASAL SPRAY | New Drug | Tier 4 | PA QL |
| NEXTSTELLIS 3 MG-14.2 MG (28) TABLET | New Drug | Tier 3 | |
| PONVORY 14-DAY STARTER PACK 2-3-4-5-6-7-8-9-10 MG TABLETS | New Drug | Tier 4 | PA QL |
| PONVORY 20 MG TABLET | New Drug | Tier 4 | PA QL |
| ROSZET 10 MG-10 MG TABLET | New Drug | Tier 3 | ST QL |
| ROSZET 10 MG-20 MG TABLET | New Drug | Tier 3 | ST QL |
| ROSZET 10 MG-40 MG TABLET | New Drug | Tier 3 | ST QL |
| ROSZET 10 MG-5 MG TABLET | New Drug | Tier 3 | ST QL |
| rufinamide 200 mg tablet | New Drug | Tier 4 | PA |
| rufinamide 400 mg tablet | New Drug | Tier 4 | PA |
| SKYRIZI 150 MG/ML SUBCUTANEOUS PEN INJECTOR | New Drug | Tier 4 | PA QL |
| SKYRIZI 150 MG/ML SUBCUTANEOUS SYRINGE | New Drug | Tier 4 | PA QL |
| SUBSYS 1,200 MCG (600 MCG/SPRAY X2) SUBLINGUAL SPRAY | New Drug | Tier 4 | PA QL |

| Drug | Reason | Cost sharing** | Restrictions*** |
|---|----------|----------------|-----------------|
| SUBSYS 1,600 MCG (800 MCG/SPRAY X2) SUBLINGUAL SPRAY | New Drug | Tier 4 | PA QL |

New Added Products: **Effective 8/1/2021**

| Drug | Reason | Cost sharing** | Restrictions*** |
|---|--------------------|----------------|-----------------|
| HUMATIN 250 MG CAPSULE | New Drug | Tier 3 | |
| isotretinoin 25 mg capsule | New Drug | Tier 3 | |
| isotretinoin 35 mg capsule | New Drug | Tier 3 | |
| QELBREE 100 MG CAPSULE,EXTENDED RELEASE | Formulary Addition | Tier 3 | ST |
| QELBREE 150 MG CAPSULE,EXTENDED RELEASE | Formulary Addition | Tier 3 | ST |
| QELBREE 200 MG CAPSULE,EXTENDED RELEASE | Formulary Addition | Tier 3 | ST |
| TAZAROTENE 0.1 % TOPICAL FOAM | New Drug | Tier 3 | |
| tiopronin 100 mg tablet | New Drug | Tier 4 | |
| TOBRADEX ST 0.3 %-0.05 % EYE DROPS,SUSPENSION | New Drug | Tier 3 | |
| XCOPRI MAINTENANCE PACK 250MG/DAY (150 MG X 1 AND 100 MG X 1) TABLETS | New Drug | Tier 4 | QL |
| XPOVIO 100 MG/WEEK (50 MG X 2) TABLET | New Drug | Tier 4 | PA LA |
| XPOVIO 40 MG TWICE WEEK (40 MG X 2) TABLET | New Drug | Tier 4 | PA LA |
| XPOVIO 40 MG/WEEK (40 MG X 1) TABLET | New Drug | Tier 4 | PA LA |
| XPOVIO 60 MG/WEEK (60 MG X 1) TABLET | New Drug | Tier 4 | PA LA |
| XPOVIO 80 MG/WEEK (40 MG X 2) TABLET | New Drug | Tier 4 | PA LA |

New Added Products: **Effective 7/1/2021**

| Drug | Reason | Cost sharing** | Restrictions*** |
|---------------------------------------|----------|----------------|-----------------|
| brinzolamide 1 % eye drops,suspension | New Drug | Tier 3 | |
| CALCIPOTRIENE 0.005 % TOPICAL FOAM | New Drug | Tier 3 | QL |
| dolishale 90 mcg-20 mcg (28) tablet | New Drug | Tier 3 | |
| fluoxetine (pmdd) 10 mg tablet | New Drug | Tier 1 | QL |
| fluoxetine (pmdd) 20 mg tablet | New Drug | Tier 1 | |
| FOTIVDA 0.89 MG CAPSULE | New Drug | Tier 4 | PA QL LA |



| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| FOTIVDA 1.34 MG CAPSULE | New Drug | Tier 4 | PA QL LA |
| HUMIRA(CF) PEN PEDIATRIC ULCER COLITIS STARTER 80 MG/0.8 ML SUBCUT KIT | New Drug | Tier 4 | PA QL |
| hydrocodone bitartrate er 100 mg tablet, crush resist,extend.rel. 24hr | New Drug | Tier 4 | PA QL |
| hydrocodone bitartrate er 120 mg tablet, crush resist,extend.rel. 24hr | New Drug | Tier 4 | PA QL |
| hydrocodone bitartrate er 20 mg tablet,crush resist,extended rel. 24hr | New Drug | Tier 3 | PA QL |
| hydrocodone bitartrate er 30 mg tablet,crush resist,extended rel. 24hr | New Drug | Tier 3 | PA QL |
| hydrocodone bitartrate er 40 mg tablet,crush resist,extended rel. 24hr | New Drug | Tier 3 | PA QL |
| hydrocodone bitartrate er 60 mg tablet,crush resist,extended rel. 24hr | New Drug | Tier 3 | PA QL |
| hydrocodone bitartrate er 80 mg tablet,crush resist,extended rel. 24hr | New Drug | Tier 4 | PA QL |
| pregabalin er 165 mg tablet, extended release 24 hr | New Drug | Tier 3 | PA QL |
| pregabalin er 330 mg tablet, extended release 24 hr | New Drug | Tier 3 | PA QL |
| pregabalin er 82.5 mg tablet, extended release 24 hr | New Drug | Tier 3 | PA QL |
| THYQUIDITY 20 MCG/ML ORAL SOLUTION | New Drug | Tier 3 | |
| TRAMADOL ER 100 MG CAPSULE 24H,EXTENDED RELEASE(25-75) | New Drug | Tier 3 | PA QL |
| TRAMADOL ER 200 MG CAPSULE 24H,EXTENDED RELEASE(25-75) | New Drug | Tier 3 | PA QL |
| TRAMADOL ER 300 MG CAPSULE 24 HR,EXTENDED RELEASE | New Drug | Tier 3 | PA QL |
| unithroid 137 mcg tablet | New Drug | Tier 1 | |
| vestura (28) 3 mg-0.02 mg tablet | New Drug | Tier 1 | |
| XTANDI 40 MG TABLET | New Drug | Tier 4 | PA QL |
| XTANDI 80 MG TABLET | New Drug | Tier 4 | PA QL |
| zafemy 150 mcg-35 mcg/24 hr transdermal patch | New Drug | Tier 3 | |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



New Added Products: **Effective 6/1/2021**

| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| accutane 20 mg capsule | New Drug | Tier 3 | |
| accutane 30 mg capsule | New Drug | Tier 3 | |
| accutane 40 mg capsule | New Drug | Tier 3 | |
| acetaminophen 320.5 mg-caffeine 30 mg-dihydrocodeine 16 mg capsule | New Drug | Tier 1 | QL |
| CYCLOPHOSPHAMIDE 25 MG TABLET | New Drug | Tier 2 | PA |
| CYCLOPHOSPHAMIDE 50 MG TABLET | New Drug | Tier 2 | PA |
| desogestrel 0.15 mg-ethinyl estradiol 0.03 mg tablet | New Drug | Tier 1 | |
| droxidopa 100 mg capsule | New Drug | Tier 4 | PA |
| droxidopa 200 mg capsule | New Drug | Tier 4 | PA |
| droxidopa 300 mg capsule | New Drug | Tier 4 | PA |
| FELBATOL 600 MG/5 ML ORAL SUSPENSION | New Drug | Tier 4 | |
| GEMTESA 75 MG TABLET | New Drug | Tier 3 | |
| GRALISE 300 MG TABLET,EXTENDED RELEASE | New Drug | Tier 2 | PA QL |
| GRALISE 600 MG TABLET,EXTENDED RELEASE | New Drug | Tier 2 | PA QL |
| HETLIOZ LQ 4 MG/ML ORAL SUSPENSION | New Drug | Tier 4 | PA QL |
| IMPAVIDO 50 MG CAPSULE | New Drug | Tier 4 | PA |
| LUCEMYRA 0.18 MG TABLET | New Drug | Tier 4 | PA |
| NALFON 400 MG CAPSULE | New Drug | Tier 3 | ST |
| OZEMPIC 1 MG/DOSE (4 MG/3 ML) SUBCUTANEOUS PEN INJECTOR | New Drug | Tier 2 | PA QL |
| RELTONE 200 MG CAPSULE | New Drug | Tier 4 | |
| RELTONE 400 MG CAPSULE | New Drug | Tier 4 | |
| SYMJEPI 0.15 MG/0.3 ML INJECTION SYRINGE (FOR 33 LB TO 66 LB PATIENTS) | New Drug | Tier 3 | QL |
| SYMJEPI 0.3 MG/0.3 ML INJECTION SYRINGE | New Drug | Tier 3 | QL |
| UKONIQ 200 MG TABLET | New Drug | Tier 4 | PA QL LA |
| ZILXI 1.5 % TOPICAL FOAM | New Drug | Tier 3 | ST |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



New Added Products: **Effective 5/1/2021**

| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| BRONCHITOL 40 MG CAPSULE WITH INHALATION DEVICE | New Drug | Tier 4 | PA |
| CALAN SR 180 MG TABLET,EXTENDED RELEASE | New Drug | Tier 3 | |
| disulfiram 500 mg tablet | New Drug | Tier 1 | |
| emtricitabine 100 mg-tenofovir disoproxil fumarate 150 mg tablet | New Drug | Tier 4 | |
| emtricitabine 133 mg-tenofovir disoproxil fumarate 200 mg tablet | New Drug | Tier 4 | |
| emtricitabine 167 mg-tenofovir disoproxil fumarate 250 mg tablet | New Drug | Tier 4 | |
| KLISYRI 1 % TOPICAL OINTMENT IN PACKET | New Drug | Tier 4 | |
| loteprednol etabonate 0.5 % eye gel drops | New Drug | Tier 2 | |
| lubiprostone 24 mcg capsule | New Drug | Tier 3 | ST QL |
| lubiprostone 8 mcg capsule | New Drug | Tier 3 | ST QL |
| LUPKYNIS 7.9 MG CAPSULE | New Drug | Tier 4 | PA LA |
| LYLLANA 0.025 MG/24 HR TRANSDERMAL PATCH | New Drug | Tier 1 | PA QL |
| LYLLANA 0.0375 MG/24 HR TRANSDERMAL PATCH | New Drug | Tier 1 | PA QL |
| LYLLANA 0.05 MG/24 HR TRANSDERMAL PATCH | New Drug | Tier 1 | PA QL |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| LYLLANA 0.075 MG/24 HR TRANSDERMAL PATCH | New Drug | Tier 1 | PA QL |
| LYLLANA 0.1 MG/24 HR TRANSDERMAL PATCH | New Drug | Tier 1 | PA QL |
| MAYZENT STARTER PACK 0.25 MG (12 TABS) TABLETS | New Drug | Tier 4 | PA QL |
| meloxicam submicronized 10 mg capsule | New Drug | Tier 3 | ST |
| meloxicam submicronized 5 mg capsule | New Drug | Tier 3 | ST QL |
| NYMYO 0.25 MG-35 MCG TABLET | New Drug | Tier 3 | |
| ONGENTYS 25 MG CAPSULE | New Drug | Tier 3 | PA |
| PERIOGARD 0.12 % MOUTHWASH | New Drug | Tier 1 | |
| ROWEEPRA 500 MG TABLET | New Drug | Tier 1 | |
| TEMIXYS 300 MG-300 MG TABLET | New Drug | Tier 4 | |
| TEMOVATE 0.05 % TOPICAL CREAM | New Drug | Tier 3 | QL |
| TEPMETKO 225 MG TABLET | New Drug | Tier 4 | PA LA |
| TRI-NYMYO 0.18/0.215/0.25 MG-35 MCG(28) TABLET | New Drug | Tier 3 | |
| VERQUVO 10 MG TABLET | New Drug | Tier 3 | QL |
| VERQUVO 2.5 MG TABLET | New Drug | Tier 3 | QL |
| VERQUVO 5 MG TABLET | New Drug | Tier 3 | QL |
| XELJANZ 1 MG/ML ORAL SOLUTION | New Drug | Tier 4 | PA QL |

New Added Products: **Effective 4/1/2021**

| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| ACUVAIL (PF) 0.45 % EYE DROPS IN A DROPPERETTE | New Drug | Tier 3 | |
| CYSTADROPS 0.37 % EYE DROPS | New Drug | Tier 4 | PA |
| DIFICID 40 MG/ML ORAL SUSPENSION | New Drug | Tier 4 | QL |
| fluocinonide 0.05 % topical cream | New Drug | Tier 1 | QL |
| HEMADY 20 MG TABLET | New Drug | Tier 3 | |
| ICLUSIG 10 MG TABLET | New Drug | Tier 4 | PA QL |
| ICLUSIG 30 MG TABLET | New Drug | Tier 4 | PA QL |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



| Drug | Reason | Cost sharing** | Restrictions*** |
|---|--------------------|----------------|-----------------|
| IMPEKLO 0.05 % TOPICAL LOTION IN PUMP | Formulary Addition | Tier 3 | QL |
| ivermectin 0.5 % lotion | New Drug | Tier 3 | |
| LOPRESSOR 50 MG TABLET | New Drug | Tier 3 | |
| LYLEQ 0.35 MG TABLET | New Drug | Tier 3 | |
| nitazoxanide 500 mg tablet | New Drug | Tier 4 | |
| NYLIA 7/7/7 (28) 0.5/0.75/1 MG-35 MCG TABLET | New Drug | Tier 3 | |
| ORGOVYX 120 MG TABLET | New Drug | Tier 4 | PA QL LA |
| REDITREX (PF) 10 MG/0.4 ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| REDITREX (PF) 12.5 MG/0.5 ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| REDITREX (PF) 15 MG/0.6 ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| REDITREX (PF) 17.5 MG/0.7 ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| REDITREX (PF) 20 MG/0.8 ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| REDITREX (PF) 22.5 MG/0.9 ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| REDITREX (PF) 25 MG/ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| REDITREX (PF) 7.5 MG/0.3 ML SUBCUTANEOUS SYRINGE | Formulary Addition | Tier 3 | |
| TILIA FE 1-20 (5)/1-30(7)/1MG-35MCG(9) TABLET | New Drug | Tier 1 | |
| TRELEGY ELLIPTA 200 MCG-62.5 MCG-25 MCG POWDER FOR INHALATION | New Drug | Tier 2 | QL |
| VESICARE LS 1 MG/ML ORAL SUSPENSION | New Drug | Tier 3 | |
| ZUBSOLV 0.7 MG-0.18 MG SUBLINGUAL TABLET | New Drug | Tier 2 | QL |

New Added Products: **Effective 3/1/2021**

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



| Drug | Reason | Cost sharing** | Restrictions*** |
|---|--------------------|----------------|-----------------|
| abiraterone 500 mg tablet | New Drug | Tier 4 | PA QL |
| ALA-CORT 2.5 % TOPICAL CREAM | New Drug | Tier 1 | |
| asenapine 10 mg sublingual tablet | New Drug | Tier 4 | QL |
| asenapine 2.5 mg sublingual tablet | New Drug | Tier 4 | QL |
| asenapine 5 mg sublingual tablet | New Drug | Tier 4 | QL |
| diltiazem er 180 mg tablet,extended release 24 hr | New Drug | Tier 1 | |
| diltiazem er 240 mg tablet,extended release 24 hr | New Drug | Tier 1 | |
| diltiazem er 300 mg tablet,extended release 24 hr | New Drug | Tier 1 | |
| diltiazem er 360 mg tablet,extended release 24 hr | New Drug | Tier 1 | |
| dimethyl fumarate 120 mg (14)-240 mg (46) capsule,delayed release | New Drug | Tier 4 | PA QL |
| EPCLUSA 200 MG-50 MG TABLET | New Drug | Tier 4 | PA QL |
| EYSUVIS 0.25 % EYE DROPS,SUSPENSION | Formulary Addition | Tier 3 | PA QL |
| HUMIRA(CF) PEN 80 MG/0.8 ML SUBCUTANEOUS KIT | New Drug | Tier 4 | PA QL |
| ICLEVIA 0.15 MG-30 MCG (91) TABLETS,3 MONTH DOSE PACK | New Drug | Tier 3 | |
| icosapent ethyl 1 gram capsule | New Drug | Tier 1 | |
| IMPEKLO 0.05 % TOPICAL LOTION IN PUMP | New Drug | Tier 4 | QL |
| levothyroxine 100 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 112 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 125 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 13 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 137 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 150 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 175 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 200 mcg capsule | New Drug | Tier 3 | |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| levothyroxine 25 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 50 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 75 mcg capsule | New Drug | Tier 3 | |
| levothyroxine 88 mcg capsule | New Drug | Tier 3 | |
| norethindrone 1 mg-ethin. estradiol 20 mcg (24)-iron 75 mg (4) capsule | New Drug | Tier 3 | |
| NYVEPRIA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE | New Drug | Tier 4 | PA |
| ONUREG 200 MG TABLET | New Drug | Tier 4 | PA |
| ONUREG 300 MG TABLET | New Drug | Tier 4 | PA |
| ORLADEYO 110 MG CAPSULE | New Drug | Tier 4 | PA LA |
| ORLADEYO 150 MG CAPSULE | New Drug | Tier 4 | PA LA |
| RETACRIT 20,000 UNIT/2 ML INJECTION SOLUTION | New Drug | Tier 2 | PA |
| RETACRIT 20,000 UNIT/ML INJECTION SOLUTION | New Drug | Tier 4 | PA |
| rufinamide 40 mg/ml oral suspension | New Drug | Tier 4 | PA |
| SUTAB 1.479 GRAM-0.188 GRAM TABLET | New Drug | Tier 3 | |
| XYWAV 0.5 GRAM/ML ORAL SOLUTION | New Drug | Tier 4 | PA QL LA |

New Added Products: **Effective 2/1/2021**

| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| AIRDUO DIGIHALER 113 MCG-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR | New Drug | Tier 3 | QL |
| AIRDUO DIGIHALER 232 MCG-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR | New Drug | Tier 3 | QL |
| AIRDUO DIGIHALER 55 MCG-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR | New Drug | Tier 3 | QL |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| ALKINDI SPRINKLE 0.5 MG CAPSULE | New Drug | Tier 3 | |
| ALKINDI SPRINKLE 1 MG CAPSULE | New Drug | Tier 3 | |
| ALKINDI SPRINKLE 2 MG CAPSULE | New Drug | Tier 4 | |
| ALKINDI SPRINKLE 5 MG CAPSULE | New Drug | Tier 4 | |
| ARMONAIR DIGIHALER 113 MCG/ACTUATION AEROSOL POWDER BREATH ACT, SENSOR | New Drug | Tier 3 | QL |
| ARMONAIR DIGIHALER 232 MCG/ACTUATION AEROSOL POWDER BREATH ACT, SENSOR | New Drug | Tier 3 | QL |
| ARMONAIR DIGIHALER 55 MCG/ACTUATION AEROSOL POWDER BREATH ACT, SENSOR | New Drug | Tier 3 | QL |
| BAFIERTAM 95 MG CAPSULE,DELAYED RELEASE | New Drug | Tier 4 | PA QL |
| BREZTRI AEROSPHERE 160 MCG-9MCG-4.8MCG/ACTUATION HFA AEROSOL INHALER | New Drug | Tier 2 | QL |
| deferiprone 500 mg tablet | New Drug | Tier 4 | PA |
| DIACOMIT 250 MG CAPSULE | New Drug | Tier 4 | |
| DIACOMIT 250 MG ORAL POWDER PACKET | New Drug | Tier 4 | |
| DIACOMIT 500 MG CAPSULE | New Drug | Tier 4 | |
| DIACOMIT 500 MG ORAL POWDER PACKET | New Drug | Tier 4 | |
| dimethyl fumarate 120 mg capsule,delayered release | New Drug | Tier 4 | PA QL |
| dimethyl fumarate 240 mg capsule,delayered release | New Drug | Tier 4 | PA QL |
| doxycycline hyclate 80 mg tablet,delayered release | New Drug | Tier 4 | ST |
| efavirenz 400 mg-lamivudine 300 mg-tenofovir disoproxil 300 mg tablet | New Drug | Tier 4 | |
| efavirenz 600 mg-emtricitabine 200 mg-tenofovir disoproxil 300 mg tablet | New Drug | Tier 4 | |
| efavirenz 600 mg-lamivudine 300 mg-tenofovir disoproxil 300 mg tablet | New Drug | Tier 4 | |
| emtricitabine 200 mg capsule | New Drug | Tier 1 | |
| emtricitabine 200 mg-tenofovir disoproxil fumarate 300 mg tablet | New Drug | Tier 4 | |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



| Drug | Reason | Cost sharing** | Restrictions*** |
|--|----------|----------------|-----------------|
| FARYDAK 15 MG CAPSULE | New Drug | Tier 4 | PA QL |
| fluorouracil 0.5 % topical cream | New Drug | Tier 4 | ST |
| fosfomycin tromethamine 3 gram oral packet | New Drug | Tier 3 | |
| GAVRETO 100 MG CAPSULE | New Drug | Tier 4 | PA LA |
| GEMMILY 1 MG-20 MCG (24)/75 MG (4) CAPSULE | New Drug | Tier 3 | |
| GIMOTI 15 MG/SPRAY NASAL SPRAY WITH PUMP | New Drug | Tier 4 | |
| GONITRO 400 MCG SUBLINGUAL POWDER IN A PACKET | New Drug | Tier 3 | |
| LAMPIT 120 MG TABLET | New Drug | Tier 3 | |
| LAMPIT 30 MG TABLET | New Drug | Tier 3 | |
| lapatinib 250 mg tablet | New Drug | Tier 4 | PA QL |
| LICART 1.3 % TRANSDERMAL 24 HOUR PATCH | New Drug | Tier 4 | PA QL |
| MENQUADFI (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION | New Drug | Tier 2 | |
| metyrosine 250 mg capsule | New Drug | Tier 4 | PA |
| NITROLINGUAL 400 MCG/SPRAY | New Drug | Tier 3 | |
| ONGENTYS 50 MG CAPSULE | New Drug | Tier 3 | PA |
| peg3350 100 gram-sod sulf 7.5 gram-nacl-kcl-ascorbate-c oral pwdr pack | New Drug | Tier 3 | |
| sapropterin 100 mg oral powder packet | New Drug | Tier 4 | PA |
| sapropterin 100 mg soluble tablet | New Drug | Tier 4 | PA |
| sapropterin 500 mg oral powder packet | New Drug | Tier 4 | PA |
| SEMGLEE PEN U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS | New Drug | Tier 3 | ST |
| SEMGLEE U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION | New Drug | Tier 3 | ST |
| spinosad 0.9 % topical suspension | New Drug | Tier 3 | |
| tavaborole 5 % topical solution with applicator | New Drug | Tier 3 | |
| timolol maleate (pf) 0.5 % eye drops in a dropperette | New Drug | Tier 3 | |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



| Drug | Reason | Cost sharing** | Restrictions*** |
|---|----------|----------------|-----------------|
| tobramycin 300 mg/4 ml solution for nebulization | New Drug | Tier 4 | PA QL |
| tolvaptan 15 mg tablet | New Drug | Tier 4 | PA |
| TRIDERM 0.5 % TOPICAL CREAM | New Drug | Tier 1 | |
| TRULICITY 3 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR | New Drug | Tier 2 | PA QL |
| TRULICITY 4.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR | New Drug | Tier 2 | PA QL |

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



For more information about how these changes may affect your cost-sharing, such as copayments or coinsurance, or for more information about asking for an updated coverage determination or a formulary exception, please see the plan Evidence of Coverage.

Alternative drugs are drugs in the same therapeutic category/class as the affected drug. Only your doctor can determine alternative drugs that are appropriate for you given the individualized nature of drug therapy. Please talk to your doctor about any changes or recommendations to your medical care and prescription drug therapy. Alternative drugs and additional information about formulary changes can be found on the plan formulary,

*Consult your Medical provider for changes or recommendations to your medical care and prescription therapy

**Please consult the plan benefit design for copay/coinsurance amounts

***Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist
[LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy ACS-O4T

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2022.

This document includes EmblemHealth Medicare PDP partial formulary as of September 1, 2021. For a complete, updated formulary, please visit our Web site at <http://www.emblemhealth.com/medicare> or call the Customer Service number below:

For alternative formats or language, please call Customer Service toll free at:
EmblemHealth Medicare PDP: 1-800-624-2414, Monday through Sunday, 8 am to 8 pm

TTY/TDD users should call **711**, Monday through Sunday, 8 am to 8 pm

21077 v15

Updated: 9/2021

Y0026_200179_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.